TRIM21 and systemic sclerosis: Instead, anti‐SSA—particularly anti‐Ro52—may reflect distinct pathogenic mechanisms in SSc by impairing Ro52‐mediated ubiquitination activity [28], leading to increased pro‐inflammatory cytokine production, tissue injury, and progression of ILD.